Selective HDAC inhibition for the disruption of latent HIV-1 infection

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Barton, Kirston M ^a   Archin, Nancie M ^a   Keedy, Kara S ^a   Espeseth, Amy S ^c   Zhang, Yan Ling ^d   Gale, Jennifer ^d   Wagner, Florence F ^d   Holson, Edward B ^d   Margolis, David M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRD 3308; DROXINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PHYTOHEMAGGLUTININ; S 1422; SHORT HAIRPIN RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; EX VIVO STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; HDAC1 GENE; HDAC2 GENE; HDAC3 GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT VIRUS INFECTION; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS TRANSCRIPTION; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENE DELETION; GENETICS; HIV INFECTIONS; HOST PATHOGEN INTERACTION; METABOLISM; PATHOGENICITY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSFORMED CELL LINE; VIROLOGY; VIRUS LATENCY;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; GENE DELETION; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VIRUS LATENCY;

EID: 84921819652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102684     Document Type: Article

References (45)

1. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
2. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
3. Chun TW, Engel D, Berrey MM, Shea T, Corey L, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 95: 8869-8873.
4. UNAIDS (2008) 2008 Report on the global AIDS epidemic.
5. Ganchi PA, Sun SC, Greene WC, Ballard DW (1992) I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding. Mol Biol Cell 3: 1339-1352.
6. Garriga J, Peng J, Parreno M, Price DH, Henderson EE, et al. (1998) Upregulation of cyclin T1/CDK9 complexes during T cell activation. Oncogene 17: 3093-3102.
7. Okamura H, Aramburu J, Garcia-Rodriguez C, Viola JP, Raghavan A, et al. (2000) Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell 6: 539-550.
8. Williams SA, Kwon H, Chen LF, Greene WC (2007) Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol 81: 6043-6056.
9. Swiggard WJ, Baytop C, Yu JJ, Dai J, Li C, et al. (2005) Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol 79: 14179-14188.
10. Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF (2004) The multifactorial nature of HIV-1 latency. Trends Mol Med 10: 525-531.
11. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM (2004) Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18: 1101-1108.
12. Choudhary SK, Archin NM, Margolis DM (2008) Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis 197: 1162-1170.
13. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, et al. (2000) The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 74: 6790-6799.
14. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, et al. (2007) Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. The EMBO journal 26: 412-423.
15. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31.
16. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-212.
17. Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP (2009) Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 25: 883-887.
18. Savarino A, Mai A, Norelli S, El Daker S, Valente S, et al. (2009) "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 6: 52.
19. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PloS one 4: e6093.
20. Archin N, Liberty AL, Kashuba AD, Choudhary SK, Kuruc J, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature.
21. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, et al. (2009) Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 23: 1799-1806.
22. Jiang G, Espeseth A, Hazuda DJ, Margolis DM (2007) c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 81: 10914-10923.
23. Tyagi M, Karn J (2007) CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. Embo J 26: 4985-4995.
24. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, et al. (2006) NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. Embo J 25: 139-149.
25. Kutsch O, Benveniste EN, Shaw GM, Levy DN (2002) Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. Journal of virology 76: 8776-8786.
26. Jordan A, Bisgrove D, Verdin E (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. The EMBO journal 22: 1868-1877.
27. Pearson R, Kim YK, Hokello J, Lassen K, Friedman J, et al. (2008) Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol 82: 12291-12303.
28. Ferguson BS, Harrison BC, Jeong MY, Reid BG, Wempe MF, et al. (2013) Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A 110: 9806-9811.
29. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS research and human retroviruses 25: 207-212.
30. Katragadda M, Magotti P, Sfyroera G, Lambris JD (2006) Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. Journal of medicinal chemistry 49: 4616-4622.
31. Poleshko A, Palagin I, Zhang R, Boimel P, Castagna C, et al. (2008) Identification of cellular proteins that maintain retroviral epigenetic silencing: evidence for an antiviral response. J Virol 82: 2313-2323.
32. Verhoeven D, Sankaran S, Silvey M, Dandekar S (2008) Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol 82: 4016-4027.
33. Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, et al. (2009) Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol 83: 3078-3093.
34. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, et al. (2013) An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9: e1003834.
35. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, et al. (2013) BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell cycle 12: 452-462.
36. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, et al. (2011) Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. The Journal of biological chemistry 286: 22211-22218.
37. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, et al. (2012) BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. Journal of leukocyte biology 92: 1147-1154.
38. Choudhary SK, Archin NM, Margolis DM (2008) Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. The Journal of infectious diseases 197: 1162-1170.
39. Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, et al. (2010) Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther 9: 246-256.
40. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, et al. (2009) A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. Journal of virology 83: 4749-4756.
41. Lusic M, Marcello A, Cereseto A, Giacca M (2003) Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. The EMBO journal 22: 6550-6561.
42. Yang WM, Yao YL, Sun JM, Davie JR, Seto E (1997) Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. The Journal of biological chemistry 272: 28001-28007.
43. Guenther MG, Barak O, Lazar MA (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Molecular and cellular biology 21: 6091-6101.
44. Hayakawa T, Nakayama J (2011) Physiological roles of class I HDAC complex and histone demethylase. Journal of biomedicine & biotechnology 2011: 129383.
45. Hanley TM, Viglianti GA (2011) Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. Journal of virology 85: 10834-10850.